Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 7/10

vs
industry
vs
history
Cash-to-Debt No Debt
ADXS's Cash-to-Debt is ranked higher than
88% of the 1046 Companies
in the Global Biotechnology industry.

( Industry Median: 55.72 vs. ADXS: No Debt )
Ranked among companies with meaningful Cash-to-Debt only.
ADXS' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.03  Med: 4.14 Max: No Debt
Current: No Debt
0.03
No Debt
Equity-to-Asset 0.58
ADXS's Equity-to-Asset is ranked lower than
62% of the 767 Companies
in the Global Biotechnology industry.

( Industry Median: 0.69 vs. ADXS: 0.58 )
Ranked among companies with meaningful Equity-to-Asset only.
ADXS' s Equity-to-Asset Range Over the Past 10 Years
Min: -5.8  Med: -0.03 Max: 0.88
Current: 0.58
-5.8
0.88
Interest Coverage No Debt
ADXS's Interest Coverage is ranked higher than
83% of the 515 Companies
in the Global Biotechnology industry.

( Industry Median: 10000.00 vs. ADXS: No Debt )
Ranked among companies with meaningful Interest Coverage only.
ADXS' s Interest Coverage Range Over the Past 10 Years
Min: No Debt  Med: No Debt Max: No Debt
Current: No Debt
Piotroski F-Score: 4
Altman Z-Score: -5.43
Beneish M-Score: -1.53
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 4/10

vs
industry
vs
history
Operating Margin % -818.95
ADXS's Operating Margin % is ranked lower than
74% of the 800 Companies
in the Global Biotechnology industry.

( Industry Median: -105.96 vs. ADXS: -818.95 )
Ranked among companies with meaningful Operating Margin % only.
ADXS' s Operating Margin % Range Over the Past 10 Years
Min: -16623.33  Med: -1934.3 Max: -818.95
Current: -818.95
-16623.33
-818.95
Net Margin % -776.63
ADXS's Net Margin % is ranked lower than
74% of the 800 Companies
in the Global Biotechnology industry.

( Industry Median: -92.13 vs. ADXS: -776.63 )
Ranked among companies with meaningful Net Margin % only.
ADXS' s Net Margin % Range Over the Past 10 Years
Min: -8206.06  Med: -1746.85 Max: 3096.67
Current: -776.63
-8206.06
3096.67
ROE % -104.48
ADXS's ROE % is ranked lower than
76% of the 961 Companies
in the Global Biotechnology industry.

( Industry Median: -39.05 vs. ADXS: -104.48 )
Ranked among companies with meaningful ROE % only.
ADXS' s ROE % Range Over the Past 10 Years
Min: -341.26  Med: -96.61 Max: -62.63
Current: -104.48
-341.26
-62.63
ROA % -70.41
ADXS's ROA % is ranked lower than
74% of the 1052 Companies
in the Global Biotechnology industry.

( Industry Median: -32.93 vs. ADXS: -70.41 )
Ranked among companies with meaningful ROA % only.
ADXS' s ROA % Range Over the Past 10 Years
Min: -386.9  Med: -108.51 Max: 45.93
Current: -70.41
-386.9
45.93
ROC (Joel Greenblatt) % -1607.52
ADXS's ROC (Joel Greenblatt) % is ranked lower than
67% of the 1014 Companies
in the Global Biotechnology industry.

( Industry Median: -432.52 vs. ADXS: -1607.52 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
ADXS' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -27114.29  Med: -8480.66 Max: 1183.45
Current: -1607.52
-27114.29
1183.45
3-Year Revenue Growth Rate 72.40
ADXS's 3-Year Revenue Growth Rate is ranked higher than
91% of the 592 Companies
in the Global Biotechnology industry.

( Industry Median: 4.10 vs. ADXS: 72.40 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
ADXS' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: 0  Med: -100 Max: 72.4
Current: 72.4
0
72.4
3-Year EBITDA Growth Rate 28.60
ADXS's 3-Year EBITDA Growth Rate is ranked higher than
78% of the 701 Companies
in the Global Biotechnology industry.

( Industry Median: 2.20 vs. ADXS: 28.60 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
ADXS' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: -30.2  Med: -16.9 Max: 41.1
Current: 28.6
-30.2
41.1
3-Year EPS without NRI Growth Rate 33.50
ADXS's 3-Year EPS without NRI Growth Rate is ranked higher than
83% of the 683 Companies
in the Global Biotechnology industry.

( Industry Median: -1.10 vs. ADXS: 33.50 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
ADXS' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: -42.1  Med: -7.2 Max: 33.5
Current: 33.5
-42.1
33.5
GuruFocus has detected 1 Warning Sign with Advaxis Inc ADXS.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» ADXS's 30-Y Financials

Financials (Next Earnings Date: 2018-03-09)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q1 2017

ADXS Guru Trades in Q1 2017

Paul Tudor Jones 34,700 sh (New)
» More
Q2 2017

ADXS Guru Trades in Q2 2017

Paul Tudor Jones Sold Out
» More
Q3 2017

ADXS Guru Trades in Q3 2017

Paul Tudor Jones 16,580 sh (New)
» More
Q4 2017

ADXS Guru Trades in Q4 2017

Jim Simons 492,394 sh (New)
Paul Tudor Jones Sold Out
» More
» Details

Insider Trades

Latest Guru Trades with ADXS

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Advaxis Inc does not have enough historical financial data to display Peter Lynch Chart.

Business Description

Industry: Biotechnology » Biotechnology    NAICS: 325414    SIC: 2834
Compare:OSL:TRVX, ROCO:6461, NAS:ORMP, AMEX:AST, ROCO:8279, TPE:1734, TSXV:EMC, NAS:MDWD, XPAR:ADVIC, LSE:MTFB, TSE:4576, AMEX:OCX, NAS:CRIS, NAS:KALV, ROCO:4130, OSTO:CELLNK B, NAS:BLRX, NAS:CKPT, XCNQ:VGW, TSE:4572 » details
Traded in other countries:FAD1.Germany,
Headquarter Location:USA
Advaxis Inc focuses on discovery, development, and commercialization of proprietary Lm (Listeria monocytogenes)-LLO (Listeriolysin O) cancer immunotherapies.

Advaxis Inc is a clinical stage biotechnology company operating in the United States. It focuses on discovery, development, and commercialization of proprietary Lm (Listeria monocytogenes)-LLO (Listeriolysin O) cancer immunotherapies. These immunotherapies are based on a platform technology which utilizes live attenuated Listeria monocytogenes (Lm) bioengineered to secrete antigen/adjuvant fusion proteins. The company's immunotherapy products based on Lm-LLO immunotherapy are Axalimogene filolisbac (AXAL) which targets Human Papilloma Virus (HPV) - associated cancers and ADXS-PSA which targets Prostate Specific Antigen (PSA) associated with prostate cancer.

Top Ranked Articles about Advaxis Inc

Research Report Identifies Diebold, Liberty TripAdvisor, Paycom Software, BJ's Restaurants, Advaxis, and Sanmina with Renewed Outlook — Fundamental Analysis, Calculating Forward Movement
3 Stocks Move on Thursday Hovnanian Enterprises, Bed Bath & Beyond, Advaxis impacted by quarterly results
Shares of Hovnanian Enterprises Inc. (NYSE:HOV) jumped more than 2% on the back of the company reporting its financial results for the fourth quarter of fiscal 2018, which ended Oct. 31. The company posted adjusted EPS of eight cents on revenue of $721.69 million, which represented a 10.4% decline from the prior-year quarter. The company beat EPS expectations by six cents, and revenue beat the consensus estimate by $113.02 million. Read more...
Aratana Therapeutics Granted Conditional License for a Canine Osteosarcoma Therapeutic
Analysis: Positioning to Benefit within Diebold, Liberty TripAdvisor, Paycom Software, First American, Advaxis, and Sanmina — Research Highlights Growth, Revenue, and Consolidated Results
Insiders Roundup: Twitter, McKesson Make Biggest Trades Largest insider trades of the Week
The GuruFocus All-in-One Screener can be used to find insider trades from the past week. Under the Insiders tab, change the settings for All Insider Buying to “$200,000+,” the duration to “Sept. 2017” and All Insider Sales to “$5,000,000+." Read more...
SHAREHOLDER ALERT: Purcell Julie & Lefkowitz LLP Is Investigating Advaxis, Inc. for Potential Breaches Of Fiduciary Duty By Its Board of Directors
Synthetic Genomics Launches cGMP Suite for Pharmaceutical Quality Manufacturing of Synthetic DNA for Advaxis' Clinical Trials
Advaxis Appoints Anthony Lombardo as Chief Business Officer
Advaxis Provides Phase 1 Data of Higher Dose Axalimogene Filolisbac

PRINCETON, N.J., March 27, 2017 (GLOBE NEWSWIRE) -- Advaxis, Inc. (NASDAQ:ADXS), a biotechnology company developing cancer immunotherapies, today published online a poster previously presented at the National Cancer Research Institute (NCRI) Cancer Conference in Liverpool that showed axalimogene filolisbac achieved durable response in a patient with persistent or recurrent metastatic (squamous or non-squamous cell) carcinoma of the cervix (PRmCC).
Nine patients who had documented disease progression after they had received curative treatments of chemotherapy and/or radiation with or without bevacizumab were enrolled in this phase 1, open-label, dose-determining study.  Axalimogene filolisbac was well-tolerated across two dose levels.  The study also established a recommended phase 2 dose of 1×1010 CFU and demonstrated antitumor activity at that dose. Axalimogene filolisbac was safely administered at 5 and 10 times the dose levels previously studied, without any significant toxicity. One patient experienced an ongoing and durable partial response.  This patient was recently featured in the Augusta Chronicle, as she is being treated at the Georgia Cancer Center at Augusta University.  Read the full Augusta Chronicle article here. “The best overall tumor response in eight of the nine enrolled patients is encouraging in evaluating the potential of axalimogene filolisbac,” said Sharad Ghamande, principal investigator and Professor and Director of Gynecologic Oncology at the Georgia Cancer Center at Augusta University.  “We were pleased to see a sustained and durable partial response in one patient, which is very rare for this kind of tumor that is unresponsive to chemotherapy, and survival in these patients is often less than 10 months. In addition, we could safely administer the drug at 5 and 10 times the dose levels previously studied, without any significant toxicity.” There was only one instance of dose-limiting toxicity, with that patient experiencing a grade 3 treatment related adverse event (TRAE) of hypotension at a dose of 5×109 CFU.  Across all doses, eight of nine patients experienced a grade 1-2 TRAE, including chills, nausea and hypotension. The poster on the phase 1 data, “High-dose treatment with ADXS11-001, a Listeria monocytogenes-listeriolysin O (Lm-LLO) immunotherapy, in women with cervical cancer: a phase I, dose-escalation study” (no. 58) is available at www.advaxis.com.  The company is preparing to initiate a phase 3 trial in PRmCC later this year. About Axalimogene Filolisbac Axalimogene filolisbac is a targeted Listeria monocytogenes (Lm)-based immunotherapy that attacks HPV-associated cancers by altering a live strain of Lm bacteria to generate cancer-fighting T cells against cancer antigens while neutralizing the tumor’s natural protections that guard the tumor microenvironment from immunologic attack.  In a phase 2 trial evaluating axalimogene filolisbac for the treatment of persistent or recurrent metastatic (squamous or non-squamous cell) carcinoma of the cervix (PRmCC), the drug candidate showed a 12-month overall survival rate of 38 percent observed in 50 patients in the trial.  This is a 52 percent improvement over the 12-month overall survival rate that was expected in the trial’s patient population based on prognostic factors. Axalimogene filolisbac has received Fast Track designation for adjuvant therapy for high-risk locally advanced cervical cancer (HRLACC) and a Special Protocol Assessment for the Phase 3 AIM2CERV trial in HRLACC patients.  The immunotherapy has also received orphan drug designation in three clinical indications. About Advaxis, Inc. Located in Princeton, N.J., Advaxis, Inc. is a biotechnology company developing multiple cancer immunotherapies based on its proprietary Lm Technology™. The Lm Technology, using bioengineered live attenuated Listeria monocytogenes (Lm) bacteria, is the only known cancer immunotherapy agent shown in preclinical studies to both generate cancer fighting T cells directed against cancer antigens and neutralize Tregs and myeloid-derived suppressor cells (MDSCs) that protect the tumor microenvironment from immunologic attack and contribute to tumor growth. Advaxis' lead Lm Technology immunotherapy, axalimogene filolisbac, targets HPV-associated cancers and is in clinical trials for three potential indications: Phase 3 in invasive cervical cancer, Phase 2 in head and neck cancer, and Phase 2 in anal cancer. The FDA has granted axalimogene filolisbac orphan drug designation for each of these three clinical settings, as well as Fast Track designation for adjuvant therapy for HRLACC patients and a SPA for the Phase 3 AIM2CERV trial in HRLACC patients. Axalimogene filolisbac has also been classified as an advanced therapy medicinal product for the treatment of cervical cancer by the EMA’s CAT. Advaxis has two additional immunotherapy products: ADXS-PSA in prostate cancer and ADXS-HER2 in HER2 expressing solid tumors, in human clinical development. In addition, Advaxis and Amgen are developing ADXS-NEO, an investigational cancer immunotherapy treatment designed to activate a patient's immune system to respond against the unique mutations, or neoepitopes, contained in and identified from each individual patient's tumor, with plans to commence a Phase 1 clinical trial in 2017. To learn more about Advaxis, visit www.advaxis.com and connect on Twitter, LinkedIn, Facebook, and YouTube. Advaxis Forward-Looking Statement This press release contains forward-looking statements, including, but not limited to, statements regarding Advaxis’ ability to develop the next generation of cancer immunotherapies, and the safety and efficacy of Advaxis’ proprietary immunotherapy, axalimogene filolisbac. These forward-looking statements are subject to a number of risks including the risk factors set forth from time to time in Advaxis’ SEC filings including, but not limited to, its report on Form 10-K for the fiscal year ended October 31, 2016, which is available at http://www.sec.gov. Any forward-looking statements set forth in this presentation speak only as of the date of this presentation. We do not intend to update any of these forward-looking statements to reflect events or circumstances that occur after the date hereof other than as required by law. You are cautioned not to place undue reliance on any forward-looking statements. CONTACTS: Company: Advaxis, Inc.
Ranya Dajani, Vice President, Business Development
[email protected]
609.250.7559 Media Contact: JPA Health Communications
David Connolly
[email protected]
617.945.9316


Read more...
EMA Certification Paves the Way for the MAA Submission for Axalimogene Filolisbac in Metastatic Cervical Cancer

PRINCETON, N.J., March 23, 2017 (GLOBE NEWSWIRE) -- Advaxis, Inc. (NASDAQ:ADXS), a biotechnology company developing cancer immunotherapies, today announced the European Medicines Agency (EMA) issued an advanced therapy medicinal product certificate for manufacturing quality and non-clinical data.  The certification procedure involved a thorough scientific evaluation over several months of the quality (CMC) data and non-clinical data by the EMA’s Committee for Advanced Therapies (CAT).  After a positive opinion from CAT, EMA issued a certificate confirming that the CMC and non-clinical data comply with the standards that apply for evaluating the Marketing Authorization Application (MAA) of axalimogene filolisbac for the treatment of metastatic cervical cancer.  Advaxis is now positioned to file the complete MAA in the second half of 2017.
“EMA’s issuance of this certification is a major milestone for Advaxis,” said Daniel J. O’Connor, President and CEO.  “With a significant portion of the MAA now reviewed and certified, we are preparing to file the complete MAA as we work to bring this innovative immunotherapy to patients with metastatic cervical cancer who have limited treatment options.” About Axalimogene Filolisbac Axalimogene filolisbac is a targeted Listeria monocytogenes (Lm)-based immunotherapy that attacks HPV-associated cancers by altering a live strain of Lm bacteria to generate cancer-fighting T cells against cancer antigens while neutralizing the tumor’s natural protections that guard the tumor microenvironment from immunologic attack.  In a phase 2 trial evaluating axalimogene filolisbac for the treatment of persistent or recurrent metastatic (squamous or non-squamous cell) carcinoma of the cervix (PRmCC), the drug candidate showed a 12-month overall survival rate of 38 percent observed in 50 patients in the trial.  This is a 52 percent improvement over the 12-month overall survival rate that was expected in the trial’s patient population based on prognostic factors. Axalimogene filolisbac has received Fast Track designation for adjuvant therapy for high-risk locally advanced cervical cancer (HRLACC) and a Special Protocol Assessment for the Phase 3 AIM2CERV trial in HRLACC patients.  The immunotherapy has also received orphan drug designation in three clinical indications. About Advaxis, Inc. Located in Princeton, N.J., Advaxis, Inc. is a biotechnology company developing multiple cancer immunotherapies based on its proprietary Lm Technology™. The Lm Technology, using bioengineered live attenuated Listeria monocytogenes (Lm) bacteria, is the only known cancer immunotherapy agent shown in preclinical studies to both generate cancer fighting T cells directed against cancer antigens and neutralize Tregs and myeloid-derived suppressor cells (MDSCs) that protect the tumor microenvironment from immunologic attack and contribute to tumor growth. Advaxis' lead Lm Technology immunotherapy, axalimogene filolisbac, targets HPV-associated cancers and is in clinical trials for three potential indications: Phase 3 in invasive cervical cancer, Phase 2 in head and neck cancer, and Phase 2 in anal cancer. The FDA has granted axalimogene filolisbac orphan drug designation for each of these three clinical settings, as well as Fast Track designation for adjuvant therapy for HRLACC patients and a SPA for the Phase 3 AIM2CERV trial in HRLACC patients. Axalimogene filolisbac has also been classified as an advanced therapy medicinal product for the treatment of cervical cancer by the EMA’s CAT. Advaxis has two additional immunotherapy products: ADXS-PSA in prostate cancer and ADXS-HER2 in HER2 expressing solid tumors, in human clinical development. In addition, Advaxis and Amgen are developing ADXS-NEO, an investigational cancer immunotherapy treatment designed to activate a patient's immune system to respond against the unique mutations, or neoepitopes, contained in and identified from each individual patient's tumor, with plans to commence a Phase 1 clinical trial in 2017. To learn more about Advaxis, visit www.advaxis.com and connect on Twitter, LinkedIn, Facebook, and YouTube. Advaxis Forward-Looking Statement This press release contains forward-looking statements, including, but not limited to, statements regarding Advaxis’ ability to develop the next generation of cancer immunotherapies, and the safety and efficacy of Advaxis’ proprietary immunotherapy, axalimogene filolisbac. These forward-looking statements are subject to a number of risks including the risk factors set forth from time to time in Advaxis’ SEC filings including, but not limited to, its report on Form 10-K for the fiscal year ended October 31, 2016, which is available at http://www.sec.gov. Any forward-looking statements set forth in this presentation speak only as of the date of this presentation. We do not intend to update any of these forward-looking statements to reflect events or circumstances that occur after the date hereof other than as required by law. You are cautioned not to place undue reliance on any forward-looking statements. CONTACTS: Company: Advaxis, Inc.
Ranya Dajani, Vice President, Business Development
[email protected]
609.250.7559 Media Contact: JPA Health Communications
David Connolly
[email protected] 
617.945.9316


Read more...

Ratios

vs
industry
vs
history
PB Ratio 1.91
ADXS's PB Ratio is ranked higher than
78% of the 944 Companies
in the Global Biotechnology industry.

( Industry Median: 4.20 vs. ADXS: 1.91 )
Ranked among companies with meaningful PB Ratio only.
ADXS' s PB Ratio Range Over the Past 10 Years
Min: 1.78  Med: 3.44 Max: 26.44
Current: 1.91
1.78
26.44
PS Ratio 8.42
ADXS's PS Ratio is ranked higher than
56% of the 731 Companies
in the Global Biotechnology industry.

( Industry Median: 11.11 vs. ADXS: 8.42 )
Ranked among companies with meaningful PS Ratio only.
ADXS' s PS Ratio Range Over the Past 10 Years
Min: 8.25  Med: 75 Max: 2037.14
Current: 8.42
8.25
2037.14
EV-to-EBIT -0.33
ADXS's EV-to-EBIT is ranked lower than
99.99% of the 261 Companies
in the Global Biotechnology industry.

( Industry Median: 22.83 vs. ADXS: -0.33 )
Ranked among companies with meaningful EV-to-EBIT only.
ADXS' s EV-to-EBIT Range Over the Past 10 Years
Min: -28.4  Med: -3.5 Max: 25.8
Current: -0.33
-28.4
25.8
EV-to-EBITDA -0.36
ADXS's EV-to-EBITDA is ranked lower than
99.99% of the 285 Companies
in the Global Biotechnology industry.

( Industry Median: 20.69 vs. ADXS: -0.36 )
Ranked among companies with meaningful EV-to-EBITDA only.
ADXS' s EV-to-EBITDA Range Over the Past 10 Years
Min: -30.6  Med: -3.7 Max: 22.8
Current: -0.36
-30.6
22.8
EV-to-Revenue 2.98
ADXS's EV-to-Revenue is ranked higher than
79% of the 776 Companies
in the Global Biotechnology industry.

( Industry Median: 12.21 vs. ADXS: 2.98 )
Ranked among companies with meaningful EV-to-Revenue only.
ADXS' s EV-to-Revenue Range Over the Past 10 Years
Min: 2.7  Med: 95.85 Max: 1645.9
Current: 2.98
2.7
1645.9
Current Ratio 3.89
ADXS's Current Ratio is ranked lower than
52% of the 1035 Companies
in the Global Biotechnology industry.

( Industry Median: 4.20 vs. ADXS: 3.89 )
Ranked among companies with meaningful Current Ratio only.
ADXS' s Current Ratio Range Over the Past 10 Years
Min: 0.02  Med: 2.37 Max: 29.36
Current: 3.89
0.02
29.36
Quick Ratio 3.89
ADXS's Quick Ratio is ranked higher than
50% of the 1035 Companies
in the Global Biotechnology industry.

( Industry Median: 3.86 vs. ADXS: 3.89 )
Ranked among companies with meaningful Quick Ratio only.
ADXS' s Quick Ratio Range Over the Past 10 Years
Min: 0.02  Med: 2.37 Max: 29.36
Current: 3.89
0.02
29.36
Days Sales Outstanding 135.10
ADXS's Days Sales Outstanding is ranked lower than
84% of the 650 Companies
in the Global Biotechnology industry.

( Industry Median: 65.03 vs. ADXS: 135.10 )
Ranked among companies with meaningful Days Sales Outstanding only.
ADXS' s Days Sales Outstanding Range Over the Past 10 Years
Min: 135.1  Med: 204.15 Max: 631.82
Current: 135.1
135.1
631.82

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -28.00
ADXS's 3-Year Average Share Buyback Ratio is ranked lower than
72% of the 744 Companies
in the Global Biotechnology industry.

( Industry Median: -13.20 vs. ADXS: -28.00 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
ADXS' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -119.8  Med: -44.9 Max: -28
Current: -28
-119.8
-28

Valuation & Return

vs
industry
vs
history
Price-to-Net-Cash 3.35
ADXS's Price-to-Net-Cash is ranked higher than
77% of the 566 Companies
in the Global Biotechnology industry.

( Industry Median: 7.67 vs. ADXS: 3.35 )
Ranked among companies with meaningful Price-to-Net-Cash only.
ADXS' s Price-to-Net-Cash Range Over the Past 10 Years
Min: 3.16  Med: 3.44 Max: 9.67
Current: 3.35
3.16
9.67
Price-to-Net-Current-Asset-Value 2.46
ADXS's Price-to-Net-Current-Asset-Value is ranked higher than
84% of the 694 Companies
in the Global Biotechnology industry.

( Industry Median: 7.04 vs. ADXS: 2.46 )
Ranked among companies with meaningful Price-to-Net-Current-Asset-Value only.
ADXS' s Price-to-Net-Current-Asset-Value Range Over the Past 10 Years
Min: 2.41  Med: 3.35 Max: 9.67
Current: 2.46
2.41
9.67
Price-to-Tangible-Book 2.09
ADXS's Price-to-Tangible-Book is ranked higher than
81% of the 864 Companies
in the Global Biotechnology industry.

( Industry Median: 5.30 vs. ADXS: 2.09 )
Ranked among companies with meaningful Price-to-Tangible-Book only.
ADXS' s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 2.05  Med: 3.32 Max: 8.93
Current: 2.09
2.05
8.93
Price-to-Median-PS-Value 0.11
ADXS's Price-to-Median-PS-Value is ranked higher than
96% of the 629 Companies
in the Global Biotechnology industry.

( Industry Median: 0.97 vs. ADXS: 0.11 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
ADXS' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.11  Med: 0.68 Max: 8
Current: 0.11
0.11
8
Earnings Yield (Greenblatt) % -277.77
ADXS's Earnings Yield (Greenblatt) % is ranked lower than
97% of the 1050 Companies
in the Global Biotechnology industry.

( Industry Median: -7.37 vs. ADXS: -277.77 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
ADXS' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: -298.3  Med: -26.95 Max: 5
Current: -277.77
-298.3
5

More Statistics

Revenue (TTM) (Mil) $12.03
EPS (TTM) $ -2.31
Beta2.52
Short Percentage of Float18.58%
52-Week Range $2.43 - 10.06
Shares Outstanding (Mil)42.28

Analyst Estimate

Oct18
Revenue (Mil $)
EBIT (Mil $)
EBITDA (Mil $)
EPS ($) -2.28
EPS without NRI ($) -2.28
EPS Growth Rate
(Future 3Y To 5Y Estimate)
N/A
Dividends per Share ($)

Piotroski F-Score Details

Piotroski F-Score: 44
Positive ROAN
Positive CFROAN
Higher ROA yoyY
CFROA > ROAY
Lower Leverage yoyY
Higher Current Ratio yoyN
Less Shares Outstanding yoyN
Higher Gross Margin yoyN
Higher Asset Turnover yoyY

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)

GF Chat

{{numOfNotice}}